Mayaderm Custom Case Solution & Analysis

1. Evidence Brief (Case Researcher)

Financial Metrics

Revenue: Reported at $45M for the fiscal year ending 2023.
Gross Margin: Currently 62%, down from 68% in 2021 due to rising raw material costs (Exhibit 2).
Marketing Spend: 22% of revenue ($9.9M), focused primarily on traditional dermatological channels.
CAC (Customer Acquisition Cost): Increased by 18% YoY to $42 per new patient.

Operational Facts

Product Portfolio: Concentrated in high-end medical-grade skincare; 80% of sales through specialized clinics.
Supply Chain: Reliance on three key suppliers for active ingredients; current lead times have expanded from 4 to 12 weeks.
Headcount: 140 full-time employees, with 60% dedicated to sales and clinical support.

Stakeholder Positions

CEO (Elena Vance): Pushing for aggressive D2C (Direct-to-Consumer) expansion to bypass clinic margins.
CFO (Marcus Thorne): Concerned about cash flow liquidity if marketing spend increases without immediate conversion.
Clinical Partners: Expressed concern that D2C expansion devalues their professional recommendation.

Information Gaps

Retention data for patients acquired through clinical vs. D2C channels.
Specific breakdown of R&D budget versus maintenance costs for the current product line.
Competitive pricing data for the top three market substitutes.

2. Strategic Analysis (Strategic Analyst)

Core Strategic Question

Should Mayaderm pivot to a D2C-led growth model, risking its clinical partner network, or deepen its commitment to the professional channel to secure premium positioning?

Structural Analysis

Value Chain: The current reliance on clinics provides high credibility but limits margin capture and customer data ownership.
Porter Five Forces: Rivalry is intense. New entrants are flooding the D2C space with lower price points, eroding Mayaderm’s market share in the mid-tier segment.

Strategic Options

Option 1: Hybrid Integration. Launch a branded D2C portal that requires a clinical referral code. Trade-off: Maintains partner trust but limits reach.
Option 2: Aggressive D2C Pivot. Full transition to online sales with tiered pricing. Trade-off: High revenue potential; high risk of alienating core clinical distribution partners.
Option 3: Premium Niche Focus. Exit the mass-market skincare segment and double down on medical-grade specialized treatments. Trade-off: Lower volume, higher margins, protects brand equity.

Preliminary Recommendation

Option 1 is the preferred path. It allows for data collection while maintaining the clinical channel that defines the product quality.

3. Implementation Roadmap (Implementation Specialist)

Critical Path

Month 1-2: Pilot the referral portal with the top 10% of clinical partners.
Month 3-5: Integrate CRM data to track conversion rates from clinic-referred patients.
Month 6+: Evaluate expansion based on churn rates and acquisition cost parity.

Key Constraints

Technical Friction: Integrating clinic systems with a D2C portal requires significant IT overhead.
Channel Conflict: Clinical partners may perceive the portal as a threat to their retail commissions.

Risk-Adjusted Implementation

Implement a revenue-sharing model where clinics receive a 5% commission on all repeat D2C purchases linked to their initial patient referrals. This aligns incentives and mitigates the risk of channel abandonment.

4. Executive Review and BLUF (Executive Critic)

BLUF

Mayaderm is trapped between a shrinking professional channel and an unproven D2C capability. The proposed hybrid model is a compromise that satisfies no one. The firm should instead segment its portfolio: move standard products to a direct-to-consumer model while reserving specialized, high-margin treatments for the clinical channel. This dual-track approach protects brand equity while capturing the growth potential of the digital segment. The current plan to force a hybrid model will likely result in a fragmented brand identity and underperformance in both channels.

Dangerous Assumption

The assumption that clinical partners will accept a referral-based portal without viewing it as a long-term threat to their revenue is naive. It underestimates the defensive reaction of clinics facing their own margin pressures.

Unaddressed Risks

Data Ownership: Moving to a D2C model requires significant investment in cybersecurity and customer data protection, which is not currently budgeted.
Operational Complexity: Managing two distinct fulfillment models (B2B for clinics and B2C for customers) will strain the current supply chain, which is already struggling with 12-week lead times.

Unconsidered Alternative

Divest the lower-margin, mass-market lines entirely to focus solely on the high-end, clinically-exclusive segment. This would reduce operational complexity and allow the company to command premium pricing without the need for mass-market marketing spend.